Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
School of Biomedical Sciences, University of Hong Kong, Hong Kong, China.
EBioMedicine. 2019 Feb;40:695-709. doi: 10.1016/j.ebiom.2019.01.010. Epub 2019 Jan 23.
Mutations in the SLC26A2 gene cause a spectrum of currently incurable human chondrodysplasias. However, genotype-phenotype relationships of SLC26A2-deficient chondrodysplasias are still perplexing and thus stunt therapeutic development.
To investigate the causative role of SLC26A2 deficiency in chondrodysplasias and confirm its skeleton-specific pathology, we generated and analyzed slc26a2 and Col2a1-Cre; slc26a2 mice. The therapeutic effect of NVP-BGJ398, an FGFR inhibitor, was tested with both explant cultures and timed pregnant females.
Two lethal forms of human SLC26A2-related chondrodysplasias, achondrogenesis type IB (ACG1B) and atelosteogenesis type II (AO2), are phenocopied by slc26a2 mice. Unexpectedly, slc26a2 chondrocytes are defective for collagen secretion, exhibiting intracellular retention and compromised extracellular deposition of ColII and ColIX. As a consequence, the ATF6 arm of the unfolded protein response (UPR) is preferentially triggered to overactivate FGFR3 signaling by inducing excessive FGFR3 in slc26a2 chondrocytes. Consistently, suppressing FGFR3 signaling by blocking either FGFR3 or phosphorylation of the downstream effector favors the recovery of slc26a2 cartilage cultures from impaired growth and unbalanced cell proliferation and apoptosis. Moreover, administration of an FGFR inhibitor to pregnant females shows therapeutic effects on pathological features in slc26a2 newborns. Finally, we confirm the skeleton-specific lethality and pathology of global SLC26A2 deletion through analyzing the Col2a1-Cre; slc26a2 mouse line.
Our study unveils a previously unrecognized pathogenic mechanism underlying ACG1B and AO2, and supports suppression of FGFR3 signaling as a promising therapeutic approach for SLC26A2-related chondrodysplasias. FUND: This work was supported by National Natural Science Foundation of China (81871743, 81730065 and 81772377).
SLC26A2 基因突变导致一系列目前无法治愈的人类软骨发育不全症。然而,SLC26A2 缺陷型软骨发育不全症的基因型-表型关系仍然令人困惑,从而阻碍了治疗的发展。
为了研究 SLC26A2 缺乏在软骨发育不全症中的致病作用,并证实其骨骼特异性病理学,我们生成并分析了 slc26a2 和 Col2a1-Cre;slc26a2 小鼠。使用 explant 培养和定时怀孕雌性小鼠测试了 FGFR 抑制剂 NVP-BGJ398 的治疗效果。
两种致命形式的人类 SLC26A2 相关软骨发育不全症,成骨不全症 IB 型(ACG1B)和软骨发育不全症 II 型(AO2),被 slc26a2 小鼠复制。出乎意料的是,slc26a2 软骨细胞在胶原蛋白分泌方面存在缺陷,表现为 ColII 和 ColIX 的细胞内滞留和细胞外沉积受损。因此,未折叠蛋白反应(UPR)的 ATF6 分支通过在 slc26a2 软骨细胞中诱导过量的 FGFR3 而优先触发 FGFR3 信号的过度激活。一致地,通过阻断 FGFR3 或其下游效应物的磷酸化来抑制 FGFR3 信号有利于从受损生长和失衡的细胞增殖和凋亡中恢复 slc26a2 软骨培养物。此外,向怀孕雌性动物给药 FGFR 抑制剂对 slc26a2 新生动物的病理特征显示出治疗效果。最后,我们通过分析 Col2a1-Cre;slc26a2 小鼠系证实了 SLC26A2 全局缺失的骨骼特异性致死性和病理学。
我们的研究揭示了 ACG1B 和 AO2 潜在的未被认识的致病机制,并支持抑制 FGFR3 信号作为治疗 SLC26A2 相关软骨发育不全症的有前途的方法。
本工作得到了国家自然科学基金(81871743、81730065 和 81772377)的支持。